Fig 2.

(A) Progression-free survival (PFS) by treatment arm for the intent-to-treat population (n = 266). PFS was defined as the time from the date of random assignment to the first date of progressive disease, which was identified by magnetic resonance imaging, evidence of neurologic progression, or death. (B) Median overall survival (OS) and 95% CI by treatment arm for the intent-to-treat population (n = 266). OS was defined as the time from the date of random assignment to death. Time-to-event estimates were calculated using the Kaplan-Meier method and were compared between regimens using the log-rank test. ENZ, enzastaurin; LOM, lomustine; HR, hazard ratio.